Comments*

 
  • Translational Research & Medicine

  • Events 

    Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM

    Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges

    Speakers: Matthew D. Breyer (Eli Lilly and Company), Frank C. Brosius (University of Michigan Medical School), Benjamin D. Humphreys (Brigham and Women's Hospital), Matthias Meier (F. Hoffmann-La Roche Ltd), Shahnaz Shahinfar (S. Shahinfar Consulting, Inc. and The Children's Hospital of Philadelphia), Katalin Susztak (University of Pennsylvania), Aliza Thompson (Food and Drug Administration)

    Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.

    Tuesday, January 27, 2015 | 8:30 AM - 4:30 PM

    Cytokine-Based Immunotherapies

    Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School, Boston, MA)
    Speakers: Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle, MA), Dario Neri (Philogen, Zurich, Switzerland), Jerome Ritz (Harvard Medical School), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology, Cambridge, MA)

    Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.

    Tuesday, February 24, 2015 | 8:30 AM - 4:30 PM

    Harnessing the Potential of Genome Editing for Drug Discovery: Translational Frontiers of in vitro and in vivo Applications

    Speakers: James Inglese (National Center for Advancing Translational Sciences), Yi Yang (Novartis Institutes for Biomedical Research)

    The emergence of genome editing technologies such as TALEN and CRISPR/Cas9 are revolutionizing our ability to rapidly engineer mammalian systems. This symposium explores the frontiers of genome editing and potential to aid therapeutic development.

    October 18 - 22, 2015

    Tenth Cooley's Anemia Symposium

    Global experts explore the biology of globin gene regulation and fetal hemoglobin induction; stem cell transplant, gene therapy strategies, and gene editing; and clinical issues in thalassemia treatment and imaging.

  • Past Events

    November 11 - 13, 2014

    Shaping the Developing Brain: Prenatal through Early Childhood
    Fifth Annual Aspen Brain Forum

    Keynote Speaker:Thomas R. Insel (National Institute of Mental Health)
    Speakers: Tracy L. Bale (University of Pennsylvania), Jay Belsky (University of California, Davis), Maureen Black (University of Maryland), Pia Britto (UNICEF), Serena Counsell (King's College London), Martha Farah (University of Pennsylvania), Edward Frongillo (University of South Carolina), Michael Georgieff (University of Minnesota), Takao Hensch (Harvard University), Sharon Lynn Kagan (Columbia University), Patricia Kuhl (Washington University), Ed Lein (Allen Institute for Brain Science), Betsy Lozoff (University of Michigan), Linda Mayes (Yale School of Medicine), Andrew N. Meltzoff (Washington University), Charles A. Nelson (Harvard University and Boston Children's Hospital), Joseph Piven (UNC School of Medicine, CIDD), Dana Suskind (University of Chicago), Nim Tottenham (UCLA)

    Discover the latest cognitive neuroscience research on infant and early childhood development; social, family, and nutritional factors that cause lasting changes to the brain; and intervention, education, and policy to help at-risk children.

    Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM

    Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach

    Speaker: Michael S. Conte (University of California-San Francisco), Milan Fiala (David Geffen School of Medicine at UCLA), Gabrielle Fredman (Columbia University), Bruce Levy (Harvard University, Brigham and Women's Hospital), Dipak Panigrahy (Beth Israel Deaconess Medical Center, Harvard Medical School), Mauro Perretti (Queen Mary University of London), Charles N. Serhan (Brigham & Women's Hospital, Harvard Medical School), Patricia J. Sime (University of Rochester School of Medicine), Rudolph E. Tanzi (Massachusetts General Hospital)

    Uncontrolled, chronic inflammation plays a key role in the progression of many diseases, and elucidation of biochemical pathways provides novel targets. This symposium reviews discoveries, approaches and opportunities for treatment and prevention.

    Friday, October 10, 2014 | 8:00 AM - 3:15 PM

    New Frontiers in the Neurobiology of Mental Illness

    Sold Out
    Keynote Speaker: The Honorable Patrick J. Kennedy
    Former United States Representative, Rhode Island; One Mind for Research; Kennedy Forum

    This conference will explore the translation of recent breakthroughs in neuroscience into therapies for the more than twenty-five percent of Americans suffering from mental illnesses such as schizophrenia, depression, fear and anxiety disorders, autism, and other psychiatric disorders. A keynote lecture by The Honorable Patrick J Kennedy will address strategies to simultaneously abolish the stigma surrounding mental illness in order to fully realize the potential of these new treatments to improve mental health.

    Thursday, October 9, 2014 | 8:00 AM - 4:00 PM

    Targeting Key Vulnerabilities in Pancreatic Cancer

    Keynote Speakers: Neesha Dhani (Princess Margaret Hospital, Toronto), Steven D. Leach (Memorial Sloan Kettering Cancer Center)
    Speakers: Gregory Beatty (University of Pennsylvania Perelman School of Medicine), Neesha C. Dhani (Division of Medical Oncology & Hematology, University Health Network, Princess Margaret Cancer Centre/Ontario Cancer Institute), Mikala Egeblad (Cold Spring Harbor Laboratory), Douglas T. Fearon (Weill Cornell Medical College and Cold Spring Harbor Laboratory), Elda Grabocka (Department of Biochemistry and Molecular Pharmacology, NYU Langone School of Medicine), Costas A. Lyssiotis (Weill Cornell Medical College ), George Miller (NYU Langone Medical Center), Michael Ports (Gilead Sciences), Curtis B. Thompson (Halozyme Therapeutics, Inc)

    Pancreatic cancer patients currently have limited therapeutic options. This symposium explores breakthroughs in the pathogenesis and progression of pancreatic cancer, and efforts to exploit key vulnerabilities for novel therapeutic interventions.

  • Publications 

    eBriefing

    Elucidating GPCR Functional Selectivity for Drug Development

    Organizers: John A. Allen (Pfizer), Mercedes Beyna (Pfizer), Bryan L. Roth (University of North Carolina School of Medicine), and Jennifer Henry (formerly at The New York Academy of Sciences)

    This eBriefing looks at how to exploit biased ligand signaling at GPCRs to improve therapeutics for cardiovascular and CNS disorders.

    eBriefing

    From Bacterial Immunity to Genome Editing: The 2014 Dr. Paul Janssen Award Symposium

    Featured Speakers: Emmanuelle Charpentier (Helmholtz Centre for Infection Research, Hannover Medical School, Germany; Umeå University, Sweden) and Jennifer Doudna (University of California, Berkeley; Howard Hughes Medical Institute)

    This eBriefing features Emmanuelle Charpentier and Jennifer Doudna, recipients of the 2014 Dr. Paul Janssen Award for Biomedical Research for their role in understanding and adapting the CRISPR/Cas system for genome editing.

    Annals

    Addiction Reviews

    Edited by George R. Uhl (National Institutes of Health, Baltimore, Maryland)

    The sixth installment of this annual series explores molecular and translational/therapeutic aspects of addiction.

    Volume 1327

    Annals

    The 12th OESO World Conference: Cancers of the Esophagus

    Edited by Robert Giuli (Deputy Director of OESO, Executive Director of the OESO Foundation, Paris, France) and Asad Umar (National Cancer Institute, Rockville, Maryland)

    This Annals volume presents a compilation of expert views on topics related to esophageal cancers presented at the World Organization for Specialized Studies on Diseases of the Esophagus 12th World Conference.

    Volume 1325

  • Webinar Archives

    Webinar Archive
    October 27, 2009

    Is Alzheimer's Disease Type 3 Diabetes?

    What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.

  • Translational Medicine Initiative

    Macy FoundationThe Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.

    Learn more at www.nyas.org/TransMed.